CBLI

4 - Statera Biopharma, Inc. (0001318641) (Issuer)

4 - Statera Biopharma, Inc. (0001318641) (Issuer)

DEF 14A - Statera Biopharma, Inc. (0001318641) (Filer)

4 - Statera Biopharma, Inc. (0001318641) (Issuer)

8-K - Statera Biopharma, Inc. (0001318641) (Filer)

8-K - Statera Biopharma, Inc. (0001318641) (Filer)

424B5 - Statera Biopharma, Inc. (0001318641) (Filer)

8-K - Statera Biopharma, Inc. (0001318641) (Filer)

FORT COLLINS, Colo., Aug. 31, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to change its corporate name to "Statera BioPharma, Inc." and update its ticker symbol to "STAB" effective Wednesday, September 1, 2021. As part of the name change, Statera BioPharma (NASDAQ:STAB) plans to release a new company logo and launch a new company website at www.staterabiopharma.com. The new corporate name, Statera, taken from the Latin word for "balance," and tagline "Restoring Immune Health" was chosen to better reflect the company's strategic focus on a

8-K - Cytocom, Inc. (0001318641) (Filer)

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audio archive of the second quarter 2021 corporate and financial results conference call may be accessed from the "Investors" section of the Cytocom website at https://www.cytocom.com/investors/. The replay of the webcast will be archived on the website for 90 days beginning at approximately 10:00 a.m. ET, on August 16, 2021. About Cytocom Cytocom,

10-Q - Cytocom, Inc. (0001318641) (Filer)

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.

8-K - Cytocom, Inc. (0001318641) (Filer)

FORT COLLINS, Colo., Aug. 12, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology (LJI), a not-for-profit academic institution and a world leader in immunology research. The agreement is directed to research that will support the development of potential new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune and chronic inflammatory diseases. The research will harness Cytocom's proprietary

FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021. Cytocom President and CEO, Mike K. Handley, will participate live as a featured panelist in the Healthcare Breakout session moderated by Dean Joseph Johnson on August 11, 2021. About Cytocom C

FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m. ET, to discuss its corporate and financial results for the second quarter 2021. Conference Call & Audio Webcast Details   Date    Monday, August 16, 2021   Time  8:30 a.m. ET    Telephone Access: U.S. and Canada  833-317-6003   Telephone Access: Inte

8-K - Cytocom, Inc. (0001318641) (Filer)

FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc.  (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs. "We are excited and believe that we are well positioned to further the development of our clinical-stage pipeline and showcase the power of our expanded post-merger drug development capabilities," stated Michael K. Handley, President and CEO of Cytocom. "We are strategically focused on immune-modulating

FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs. The all-stock transaction, first announced in October 2020, was formally completed on July 27, 2021. "With the Cleveland BioLabs merger completed and Cytocom now operating as a publicly-traded company, the management team at Cytocom is in the process of integrating both companies a

3 - Cytocom, Inc. (0001318641) (Issuer)

4 - Cytocom, Inc. (0001318641) (Issuer)

8-K/A - Cytocom, Inc. (0001318641) (Filer)

4 - Cytocom, Inc. (0001318641) (Issuer)

4 - Cytocom, Inc. (0001318641) (Issuer)